Optimized Interferon-gamma ELISpot Assay to Measure T Cell Responses in the Guinea Pig Model after Vaccination
January 20th, 2019
23.2K views
The development of the interferon-gamma ELISpot assay for guinea pig PBMCs allows the characterization of T-cell responses in this highly relevant model for studying infectious diseases. We have applied the assay to measure T cell responses associated with intradermal delivery of DNA vaccines.
Overview
The development of the interferon-gamma ELISpot assay for guinea pig PBMCs enables the characterization of T-cell responses in this important model for infectious diseases. This assay allows researchers to measure both the magnitude and kinetics of T-cell responses during natural infections or vaccine regimens.
Key Study Components
Area of Science
- Immunology
- Infectious Diseases
- Vaccine Development
Background
- Previous methods focused on measuring humoral immunity in guinea pigs.
- The ELISpot assay provides a way to assess T-cell responses without necropsy.
- This technique enhances data generation in the guinea pig model.
- It is crucial for studying diseases with significant T-cell involvement.
Purpose of Study
- To develop a method for measuring T-cell responses in guinea pigs.
- To refine vaccine protocols in the guinea pig model.
- To reduce reliance on less relevant animal models.
Methods Used
- Preparation of ELISpot assay plates with ethanol and PBS.
- Isolation of PBMCs using density gradient centrifugation.
- Incubation with capture antibodies and detection reagents.
- Careful handling to avoid contamination and ensure cell viability.
Main Results
- The assay successfully measures T-cell responses in guinea pigs.
- Improved definition and reduced nonspecific spots in results.
- Allows for the study of T-cell dynamics during infections and vaccinations.
- Facilitates research on diseases like TB, Ebola, and HSV.
Conclusions
- The ELISpot assay is a valuable tool for immunological studies in guinea pigs.
- It enhances the understanding of T-cell responses in infectious diseases.
- This method can lead to better vaccine development strategies.
Frequently Asked Questions
What is the main advantage of the ELISpot assay?
The main advantage is that it allows for the measurement of T-cell responses without the need for necropsy, using cells obtained from peripheral blood.
How does the ELISpot assay improve data generation?
It provides a more comprehensive understanding of T-cell dynamics, including both magnitude and kinetics of responses.
What diseases can this assay help study?
It is particularly useful for studying diseases with significant T-cell involvement, such as tuberculosis, Ebola, and herpes simplex virus.
Who demonstrated the ELISpot assay procedure?
Holly Pugh, a research associate from Inovio's Preclinical R and D Department, demonstrated the procedure.
What precautions should be taken when performing this assay?
Precautions include wearing appropriate personal protective equipment (PPE) and handling blood and reagents carefully to avoid contamination.
What is the significance of the buffy coat layer in the procedure?
The buffy coat layer contains the PBMCs, which are crucial for measuring T-cell responses in the assay.
Executive Industry Relevance
The interferon-gamma ELISpot assay for guinea pig PBMCs addresses a critical gap in preclinical immunology by enabling longitudinal tracking of T-cell responses without necropsy. This capability enhances predictive confidence in vaccine candidates targeting intracellular pathogens and supports go/no-go decisions in early discovery. The assay’s use of peripheral blood facilitates cross-functional collaboration and reduces reliance on less predictive animal models.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of vaccine-specific T-cell responses to validate immunological mechanisms of action.
- Operational Value: Provides quantitative IFN-gamma spot counts as a functional readout for target engagement and pathway modulation.
- Predictive Value: Supports mechanistic de-risking by correlating T-cell magnitude and kinetics with protective immunity in disease-relevant models.
Screening & Assay Development
- Scientific Value: Generates reproducible, quantitative data from PBMC isolates to support assay standardization across vaccine candidates.
- Operational Value: Eliminates terminal bleed requirements, enabling repeated sampling from individual animals for kinetic profiling.
- Assay Readiness: Delivers defined spot formation with reduced nonspecific background, improving signal-to-noise for compound or antigen screening.
Translational & Preclinical Research
- Translational Continuity: Bridges discovery and preclinical stages by measuring antigen-specific T-cell dynamics during vaccine regimens.
- Disease Relevance: Directly applicable to pathogens with strong T-cell dependence, including tuberculosis, Ebola, and HSV, as noted in the protocol.
- <Risk-Adjusted Advancement: Informs portfolio triage by identifying vaccine constructs that elicit robust cellular immunity.
Pipeline & Workflow Integration
The assay fits within the discovery-to-preclinical continuum, enabling immune monitoring after lead identification and prior to efficacy challenge studies.
- Discovery Biology: Supports hypothesis testing of T-cell epitopes and cytokine polarization in response to vaccine antigens.
- Screening: Delivers standardized, quantitative outputs for comparing immunogenicity across antigen designs or delivery platforms.
- Analytics: Provides IFN-gamma spot-forming unit (SFU) measurements that allow statistical comparison of immune responses across time points and treatment groups.
- Translational Research: Connects early immune profiling to preclinical efficacy by tracking antigen-specific T-cell responses in vivo.
- Enterprise Reuse: Establishes a reusable PBMC-based immunomonitoring platform applicable across infectious disease and oncology vaccine programs.
Operational & Enterprise Impact
- Scientific Value: Increases confidence in target validation by providing functional, antigen-specific T-cell data from a physiologically relevant model.
- Operational Value: Enhances reproducibility through standardized plate pretreatment, PBMC isolation, and detection steps that minimize variability.
- Strategic Value: Improves capital efficiency by reducing animal use and enabling data collection from the same subjects across multiple time points.
- Portfolio Impact: Supports risk-adjusted prioritization of vaccine candidates based on cellular immunogenicity profiles.
Implementation Considerations
- Requires expertise in immunology, cell isolation, and aseptic technique to maintain PBMC viability and assay integrity.
- Dependent on access to ELISpot plate readers, incubators, centrifuges, and reagents including anti-guinea pig IFN-gamma antibodies and BCIP/NBT substrate.
- Necessitates standardization across teams for blood processing timing, cell washing, and stimulation conditions to ensure data comparability.
- Must account for species-specific reagent validation when adapting the assay to other rodent or non-human primate models.
- Practical limitations include the need for timely blood processing to preserve cell function and the biohazard handling requirements for human or animal blood and alkaline phosphatase substrates.
Biopharma FAQs
Why does IFN-gamma ELISpot matter for target validation in guinea pigs?
It provides a functional, antigen-specific readout of T-cell activation by measuring interferon-gamma secretion, which is critical for validating immunological mechanisms of vaccine candidates in a model where humoral-only assays were previously insufficient.
How does isolating PBMCs from peripheral blood support the discovery pipeline?
It enables longitudinal sampling from individual animals without necropsy, allowing researchers to track T-cell response magnitude and kinetics across vaccine boosts or infection stages, which supports iterative design and go/no-go decisions.
What do quantitative IFN-gamma spot counts enable in vaccine evaluation?
They deliver a measurable, reproducible output for comparing antigen-specific T-cell frequencies across conditions, facilitating statistical analysis and comparative assessment of vaccine immunogenicity.
Why do replication requirements matter for cross-functional collaboration?
Replicate wells and repeated experiments ensure assay reliability and data consistency, which is essential for aligning immunology, formulation, and preclinical teams on immune response trends and decision thresholds.
What statistical analysis capabilities are required before implementing this assay?
The ability to calculate spot-forming units per million PBMCs, apply appropriate normalization, and use tests such as t-tests or ANOVA to compare groups is needed to interpret significant differences in T-cell responses across experimental conditions.
Chapters in this video
0:04
Title
0:58
Preparation of ELISpot-plates and Cell-stimulation
2:09
Blood Sample Processing
3:44
Plate Preparation and Cell-plating
4:47
Detection of Interferon-gamma Positive Spots
6:34
Results: ELISpot Assay Used to Characterize T-cell Responses in Guinea Pigs
7:15
Conclusion
